$NGNE

2 stories mentioning NGNEUpdated 90d ago

Every FINWIRES story that references NGNE, newest first.

Neurogene Insider Sold Shares Worth $300,043, According to a Recent SEC Filing

Christine Mikail Cvijic, Director, President and CFO, on May 06, 2026, sold 9,600 shares in Neurogene (NGNE) for $300,043. Following the Form 4 filing with the SEC, Cvijic has control over a total of 93,640 common shares of the company, with 93,640 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1404644/000154366326000013/xslF345X05/wk-form4_1778255465.xmlPrice: $30.50, Change: $-0.76, Percent Change: -2.43%

$NGNE

Research102d ago

Guggenheim Initiates Neurogene at Buy With $69 Price Target

Neurogene (NGNE) has an average rating of buy and mean price target of $76.43, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$NGNE

Track with the FINWIRES app suite

FolioX

Track NGNE in your portfolio

WheelAI

Analyze NGNE options with the wheel strategy

StockInsider

See market sentiment on NGNE